Abstract CAR-T cell therapy is a promising new immunotherapy for number of difficult-to-treat cancers, however, it has yet to yield broad success in glioblastoma (GBM). In particular, tumor heterogeneity presents major therapeutic challenge, and detailed understanding the complex interplay between different neoplastic, non-neoplastic, cells critical developing better treatments. Using patient-d...